ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing - - BioPharm International

ADVERTISEMENT

ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing



ProBioGen has formed an agreement with Emergent BioSolutions for a non-exclusive commercial multiproduct license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR cell line. Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent.  As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.

Source: ProBioGen

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here